CORRESPONDENCE

PIVKA-II concentrations in patients with cystic fibrosis

Montalembert *et al* report that PIVKA-II was detected in 33% of patients with cystic fibrosis, while vitamin K₁ plasma concentrations were normal.¹ It is astonishing that despite daily supplements of 5–10 mg vitamin K₁, PIVKA-II was detectable in these patients. The authors conclude that PIVKA-II is not associated with vitamin K deficiency, but with the use of antibiotics.

There is some doubt as to whether the assay for PIVKA-II used by the authors is reliable. Widdershoven *et al* compared different methods for measuring PIVKA-II and reported that techniques involving adsorption of normal factor II may result in false positive values, because the carboxylated prothrombin may not be removed completely.² Determination of PIVKA-II by monoclonal antibody was found to be the most specific and sensitive method.² We did not detect PIVKA-II in any of eight patients with cystic fibrosis who were supplemented with vitamin K₁ (4–30 mg/day).³ In only one out of 16 unsupplemented patients with cystic fibrosis was PIVKA-II found (0.16 AU/ml). This patient took antibiotics, had a low vitamin K₁ concentration of 0.06 µg/l and a Thrombotest of 56%.³

The authors do not mention vitamin K₂. Except for vitamin K₁, vitamin K₂ must be accounted for when assessing vitamin K status. Antibiotics may disturb vitamin K₂ production by intestinal flora and hence reduce the amount of total vitamin K available for the carboxylation of PIVKA-II to functional factor II. A correlation between subnormal coagulation tests and antibiotics in cystic fibrosis was reported by Komp and Selden.⁴ As there was no information on concentrations of vitamin K₂, it is impossible to establish normal values for vitamin K₁. PIVKA-II, however, is a direct reflection of the availability of total vitamin K in the liver and hence is associated with vitamin K deficiency. In our study PIVKA-II was found in only one unsupplemented patient with cystic fibrosis, and hence we conclude that vitamin K deficiency occurs infrequently in cystic fibrosis.³

EAM CORNELISSEN
AF VAN LIEBURG
CG VAN OOSTROM
LAH MONNENS

Department of Paediatrics,
University Hospital Nijmegen,
PO Box 9101, NL-6500 HB Nijmegen,
The Netherlands

- 1 Montalembert M de, Lenoir G, Sant-Raymond A, Rey J, Lefrère JJ. Increased PIVKA-II concentrations in patients with cystic fibrosis. *J Clin Pathol* 1992;45:180–1.
- 2 Widdershoven J, Munster P van, De Abreu R, *et al*. Four methods compared for measuring des-carboxy-prothrombin (PIVKA-II). *Clin Chem* 1987;33:2074–8.
- 3 Cornelissen EAM, Lieburg AF van, Motohara K, Oostrom CG van. Vitamin K status in cystic fibrosis. *Acta Paediatr Scand* (in press).
- 4 Komp DM, Selden RF. Coagulation abnormalities in cystic fibrosis. *Chest* 1970;58:501–3.

Dr Lefrère *et al* comment:

Our PIVKA-II assay, based on the activity of staphylocoagulase, is widely used in many laboratories. The results obtained with this

procedure with those of laboratories measuring PIVKA-II with monoclonal antibody, in particular in patients with hepatocellular carcinoma.^{1,2} Furthermore, we measured PIVKA-II concentrations in a large population of healthy individuals (blood donors) and obtained no false positive result in these individuals.

Dr Cornelissen *et al* do not raise the possibility of increased PIVKA-II in contexts other than vitamin K deficiency, such as hepatocellular carcinoma,^{1,2} hepatoblastoma,³ effect of oral anticoagulants⁴ and cephalosporins.⁵ Indeed, vitamin K deficiency is not the only mechanism to generate PIVKA-II. In hepatocellular carcinoma increased PIVKA-II concentration is probably due to an acquired enzymatic anomaly which disturbs the γ -carboxylation of all vitamin K dependent factors.⁶ We could not explain this increase in our patients with cystic fibrosis and without vitamin K deficiency. This increase might have been linked to the interference of certain drugs on the enzymatic system of γ -carboxylation of vitamin K dependent factors.

Dr Cornelissen does not say if the eight patients they studied with a normal PIVKA-II concentration received certain drugs (such as antibiotics). However, we agree with his conclusion: vitamin K deficiency is rare in patients with cystic fibrosis supplemented with vitamin K.

- 1 Soulier JP, Gozin D, Lefrère JJ. A new method to assay desgamma-carboxyprothrombin. Results obtained in 75 cases of hepatocellular carcinoma. *Gastroenterology* 1986;91:1258–62.
- 2 Liebman HA, Furie BC, Tong MJ, *et al*. Desgamma-carboxy (abnormal)-prothrombin as a serum marker of primary hepatocellular carcinoma. *N Engl J Med* 1984;310:1427–31.
- 3 Lefrère JJ, Armengaud D, Leclercq M, Guillaumont M, Gozin D, Alagille D. Des-gamma-carboxyprothrombin and hepatoblastoma. *J Clin Pathol* 1988;41:356.
- 4 Nelsestuen GL, Zytkevich TH, Howard JB. The mode of action of vitamin K: identification of gamma-carboxyglutamic acid as a component of prothrombin. *J Biol Chem* 1974;249:6347–50.
- 5 Bechtold H, Andrassy K, Janchen E. Evidence for impaired hepatic vitamin K₁ metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. *Thromb Haemostas* 1984;51:358–61.
- 6 Lefrère JJ, VanDreden P, Samama P. Elevation of different des-gamma-carboxyproteins in hepatocellular carcinoma. *Thromb Haemostas* 1987;58:1092.

Modifying the request behaviour of clinicians

In their recent paper, Gama *et al*¹ report that feedback of laboratory data to clinicians "modified" their request behaviour for clinical chemistry and haematology tests (reduced the numbers of tests requested). The authors clearly imply that this modification was a good thing. Their opening sentence refers to "... strategies for improving (my emphasis) laboratory use", and in their discussion they state that their results support the view "that the physicians had become more judicious (my emphasis) in their laboratory use".

In a partly similar study Bareford and Hayling² sent each consultant a monthly statement of use of the laboratory by his firm, compared with that of other clinicians. This practice, with three other interventions, they concluded, resulted in a "definite and sustained reduction in inappropriate (my emphasis) requests for laboratory investigations".

In my opinion, both groups are falling into the trap of making unjustified value judgements based on evidence for only one half of the equation: less tests = better/no worse treatment.

Modifications in clinicians' laboratory testing behaviour patterns can only be regarded as desirable or "judicious" if the new modified behaviour can be demonstrated to improve patient care, or at least to result in no worse care. Similarly, requests can only be claimed to be "inappropriate" if it is shown that leaving them out over a period results in no deterioration of clinical care. Unfortunately, it is almost impossible to measure the quality of patient care in the short term. Misdiagnoses, or inappropriate treatment resulting from laboratory tests not being done, could only be detected by worsened morbidity or mortality figures obtained over a period of years. Neither Gama *et al* nor the other group of authors cited above provide any such data to show that their clinicians were not giving their patients worse care than before as a result of curtailing their laboratory requests. In fact, Gama *et al*'s statement that as a result of their initiative "fewer outpatients were investigated, and when investigated had fewer tests performed on them" would suggest, *prima facie*, that these patients were receiving worse medical treatment than before.

T E BLECHER

Haematology Department
University Hospital, Nottingham NG7 2UH

- 1 Gama R, Nightingale PG, Broughton PMG, *et al*. Modifying the request behaviour of clinicians. *J Clin Pathol* 1992;45:248–9.
- 2 Bareford D, Hayling A. Inappropriate use of laboratory services: long term combined approach to modify request patterns. *Br Med J* 1990;301:1305–7.

Dr Gama *et al* comment:

There is ample evidence that many laboratory investigations may be unnecessary for adequate patient care^{1–4} and that the recent increased laboratory use has not been associated with an improvement in patient outcome.^{5–7} In our study,^{8,9} unlike Blecher, we made no unfounded assumption about the quality of patient care. Although we were unable to assess clinical outcome: we agree with Blecher that this, in practice, would be almost impossible to achieve. We believe it unlikely that the reduction in laboratory use through more thoughtful and discretionary ("judicious") testing adversely affected patient management. The fact that fewer outpatients were investigated suggests a reduction in venepunctures (considered unnecessary by the attendant physician) and this, contrary to Blecher's assertion, represents an improvement in the quality of patient care.

Motivation for improving laboratory use should not be limited to better quality of patient care but should also include more efficient use of laboratory and clinical resources.^{10,11} We believe that this involves tackling not only laboratory overuse¹² but also under-use¹³ and misuse. Gama R, Pickford R, Jones SR, McCauley B, Peters M. Proceedings of the ACB national meeting, 1990:63.